Bayer has taken another step toward fulfilling blockbuster ambitions for its eye drug Eylea. The German drugmaker asked European regulators to approve the vision-loss treatment for patients with diabetic macular edema. With diabetes on the rise all over the world, the new indication could offer long-term growth for the already fast-rising drug.
Regeneron once again beat expectations with its quarterly earnings. And once again, the company raised its forecast for Eylea, the vision-loss drug that's fueling much of its growth. But once again, Regeneron said that sales growth for Eylea was slowing down as patients use fewer doses.
Eye drug Eylea and blood thinner Xarelto are pretty good products for any drugmaker to have in its lineup, and Bayer's got them both. Sales of those new stars have been plentiful, and they helped the German company raise earnings 7.7% for the third quarter, the company announced Thursday.
With sales of eye drug Eylea growing at breakneck pace and a couple of promising candidates in its pipeline, Regeneron needs some more space.
With blockbuster sales of Eylea spurring some gangbuster projections for Regeneron's future, the booming biotech today launched construction of a 300,000-square-foot R&D facility at its campus in Westchester County, NY.
The positive data keep rolling in for Regeneron's Eylea. Monday, the company said its blockbuster eye drug improved vision loss in patients with a condition caused by blood clots in the retinal veins, opening up another potential avenue for its rapidly expanding market.
Herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Read the full report >>
Bayer's Eylea has a new field for fighting Lucentis. The eye drug won a new approval in Europe, in patients with macular degeneration due to central retinal vein occlusion, setting it up for another market-share battle against Novartis.
Regeneron Vice President Peter Dworkin said the company will start work on the 400,000-square-foot facility in Limerick as soon as local permits are obtained.
At a time when many companies are cutting back, Regeneron is expanding on all fronts, adding jobs and facilities across the board, from offices to manufacturing units. Most recently, the company entered the second phase of a $70 million upgrade to its plant in East Greenbush, NY.